vimarsana.com

Latest Breaking News On - Linnane pharma - Page 1 : vimarsana.com

Q2 Interim Report October - December 2023

Q2 Interim Report October - December 2023
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.

Notice of extraordinary general meeting in Hamlet Pharma AB (publ)

The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to the extraordinary general meeting on Wednesday, 17 May 2023 at 14:00 at High Court Malmö, Malmöhusvägen 1, SE-211 18 Malmö, Sweden. Registration for the meeting will commence at 13:30.

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden and who wish to accept the proposed merger consideration must carry out closer investigations regarding the applicable legislation and possible tax consequences. The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, intend to merge and create a powerful pharmaceutical company for drug development for the treatment of cancer and infectious diseases. The merged company (Hamlet Biopharma) gets a portfolio with a total of ten pharmaceutical projects, of which three projects are in phase II, where two of the projects already have positive re

Hamlet Pharma AB: Hamlet Pharma Q2 Interim Report October 2022 – December 2022

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.